Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says
Executive Summary
Pfizer wants to get its adalimumab biosimilar to market as soon as possible, but won’t say whether that’s before AbbVie's patents run out in 2023.
You may also be interested in...
Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says
But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.
Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake
Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.
Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents
Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.